Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T cells, forming ...

A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.

Panelists explore challenges in identification of patients with intermediate-risk disease and emphasize importance of risk stratification to improve outcomes with regard to NMIBC.

“I would say both there could be an increase in MRI-guided [SBRT] and there may be increase in investigation into shrinking margins with CT-guided SBRT as well,” says Amar U. Kishan, MD. In this video ...

"Despite the fact that multiple new procedures have come to light, nothing has the same excellent outcomes as HoLEP," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, discusses the key ...

All nine patients with stage III/IV ccRCC showed anti-tumor responses and remained disease-free three years post-vaccination. The vaccine induced durable T cell activation and immune responses against ...

A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.

Panelists discuss how FDA approvals have expanded options for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), with pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene ...

"It was interesting to think about the relationship between a disease process and a person's environment, and measure that and establish that relationship in a quantitative way," says William Furuyama ...

Panelists discuss how for patients with BCG-unresponsive bladder cancer, treatment selection depends on key factors including tumor characteristics (carcinoma in situ vs papillary), patient fitness, ...

This video segment discusses the frequency of encountering mCRPC patients with hepatic dysfunction, additional tests to consider, and treatment options for these patients.

If the patient is positive for prostate-specific membrane antigen (PSMA), how would you treat the patient? What is your algorithm for monitoring patients with liver dysfunction and advanced CRPC? What ...